Theragnostics/Personalized Medicine

Session Organizers:
Flavia Groppi, Universitá egli Studi di Milano, Laboratorio LASA, Italy
Suresh Srivastava, Brookhaven National Laboratory, USA

This session will be devoted to a relatively novel paradigm that involves specific individual ‘dual-purpose’ radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy, and which, when molecularly (selectively) targeted using appropriate carriers, would allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient using the same radiopharmaceutical. The selection criteria, production, and the nuclear, physical, and chemical properties of the more promising “theragnostic” radionuclides, including those that are currently being studied and evaluated, and those that warrant future investigations will be discussed. This includes resolving the lack of availability, in sufficient quantities and at reasonable cost, of a majority of the best candidate theragnostic radionuclides in a no-carrier-added (NCA) form.

Invited Papers

Theragnostic radiopharmaceuticals for the imaging plus treatment of cancer and other inflammatory disorders
Suresh Srivastava, Brookhaven National Laboratory, United States

Preliminary Production of Ac-225 by Spallation Reaction on Th-232
Leonard Mausner, Brookhaven National Laboratory, United States

Low energy proton irradiation of 86SrCl2 at BLIP to produce PET radioisotope 86Y
Dmitri Medvedev, Brookhaven National Laboratory, United States

Multifunctional radionanomedicine: a new theranostic approach
Flavia Groppi, L.A.S.A. Laboratory, Università degli Studi di Milano and INFN Milano, Italy

New radioisotopes for innovative theranostic approach in nuclear medicine
Dr. Mickaël Bourgeois, ARRONAX Cyclotron, Nantes Nuclear Medicine Department, France

Targeting Genomic Biomarkers for Diagnosis and Therapy
Mathew L. Thakur, Thomas Jefferson University, United States